These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 26927029

  • 1. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV, Sanmartí R, Cañete JD.
    Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
    [Abstract] [Full Text] [Related]

  • 2. Safety profile of biological therapies for treating rheumatoid arthritis.
    Cañete JD, Hernández MV, Sanmartí R.
    Expert Opin Biol Ther; 2017 Sep; 17(9):1089-1103. PubMed ID: 28657381
    [Abstract] [Full Text] [Related]

  • 3. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A, Koenig AS, Bananis E, Singh A.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [Abstract] [Full Text] [Related]

  • 4. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH.
    Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
    [Abstract] [Full Text] [Related]

  • 5. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
    [No Abstract] [Full Text] [Related]

  • 6. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K, Kirkham B.
    Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
    [Abstract] [Full Text] [Related]

  • 7. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 8. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H, Kavanaugh A.
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [Abstract] [Full Text] [Related]

  • 9. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
    van Ingen IL, Lamers-Karnebeek F, Jansen TL.
    Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268
    [Abstract] [Full Text] [Related]

  • 10. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ, Ranganathan P.
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group.
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [Abstract] [Full Text] [Related]

  • 12. Anti-TNF treatment in rheumatoid arthritis.
    Geiler J, Buch M, McDermott MF.
    Curr Pharm Des; 2011 May; 17(29):3141-54. PubMed ID: 21864263
    [Abstract] [Full Text] [Related]

  • 13. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.
    Conti F, Atzeni F, Massaro L, Chiara Gerardi M, Gremese E, Passiu G, Carletto A, Malavolta N, Foti R, Ramonda R, Sarzi-Puttini P.
    Rheumatology (Oxford); 2018 Oct 01; 57(57 Suppl 7):vii11-vii22. PubMed ID: 30289537
    [Abstract] [Full Text] [Related]

  • 14. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
    Manders SH, Kievit W, Braakman-Jansen AL, Brus HL, Hendriks L, Fransen J, van de Laar MA, van Riel PL.
    J Rheumatol; 2014 Jul 01; 41(7):1263-9. PubMed ID: 24833758
    [Abstract] [Full Text] [Related]

  • 15. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis.
    Phillips C, Zeringue AL, McDonald JR, Eisen SA, Ranganathan P.
    PLoS One; 2015 Jul 01; 10(11):e0143286. PubMed ID: 26599370
    [Abstract] [Full Text] [Related]

  • 16. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR.
    Arthritis Care Res (Hoboken); 2015 Dec 01; 67(12):1671-8. PubMed ID: 26018115
    [Abstract] [Full Text] [Related]

  • 17. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
    Mushtaq S, Goodman SM, Scanzello CR.
    Am J Ther; 2011 Sep 01; 18(5):426-34. PubMed ID: 20216205
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec 01; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 19. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N.
    Mod Rheumatol; 2015 Mar 01; 25(2):251-6. PubMed ID: 25211402
    [Abstract] [Full Text] [Related]

  • 20. Management of rheumatoid arthritis.
    Handa R.
    Natl Med J India; 2004 Mar 01; 17(3):143-51. PubMed ID: 15253402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.